EGFR-targeted therapeutics: Focus on SCCHN and NSCLC

TheScientificWorldJournal

Volumn 8, Issue , 2008, Pages 909-919

  Sattler, Martin ^a,b   Abidoye, Oyewale ^c   Salgia, Ravi ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cetuximab; Epidermal growth factor receptor; Erbitux; Head and neck cancer; Lung cancer; Targeted therapy

Indexed keywords

4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AE 788; BEVACIZUMAB; BIBW 2992; CANERTINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; GEFITINIB; GEMCITABINE; HKI 357; HUMAX EGFR; LAPATINIB; MATUZUMAB; MDX 447; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 806; NAVELBINE; NIMOTUZUMAB; PANITUMUMAB; PELITINIB; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; ZALUTUMUMAB;

ADJUVANT THERAPY; ADVANCED CANCER; AMINOTRANSFERASE BLOOD LEVEL; ANGIOGENESIS; ASTHENIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG SAFETY; DRUG TARGETING; ENZYME INHIBITION; FLUORESCENCE IN SITU HYBRIDIZATION; FOOD AND DRUG ADMINISTRATION; GENE AMPLIFICATION; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; HYPOPHARYNX CANCER; LARYNX CANCER; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; OROPHARYNX CANCER; PATIENT SELECTION; PHARMACOGENOMICS; PROTEIN EXPRESSION; RASH; RECEPTOR GENE; REVIEW; SIDE EFFECT; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 52249116587     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2008.117     Document Type: Review

References (58)

1. Bernier, J. and Schneider, D. (2007) Cetuximab combined with radiotherapy: an alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck? Eur. J. Cancer 43, 35-45.
2. Langer, C.J. (2004) Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC. Int. J. Radiat. Oncol. Biol. Phys. 58, 991-1002.
3. Hotta, K., Matsuo, K., Ueoka, H., et al. (2004) Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 22, 3852-3859.
4. Normanno, N., De Luca, A., Bianco, C., et al. (2006) Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366, 2-16.
5. Mendelsohn, J. (2001) The epidermal growth factor receptor as a target for cancer therapy. Endocr. Relat. Cancer 8, 3-9.
6. Nicholson, R.I., Gee, J.M., and Harper, M.E. (2001) EGFR and cancer prognosis. Eur. J. Cancer 37(Suppl 4), S9-15.
7. Kang, X., Patel, D., Ng, S., et al. (2007) High affinity Fc receptor binding and potent induction of antibody-dependent cellular cytotoxicity (ADCC) in vitro by anti-epidermal growth factor receptor antibody cetuximab. J. Clin. Oncol. (Meeting Abstracts) 25, 3041.
8. Dittmann, K., Mayer, C., Fehrenbacher, B., et al. (2005) Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J. Biol. Chem. 280, 31182-31189.
9. Tejpar, S., Peeters, M., Humblet, Y., et al. (2007) Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data. J. Clin. Oncol. (Meeting Abstracts) 25, 4037.
10. Hanna, N., Lilenbaum, R., Ansari, R., et al. (2006) Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J. Clin. Oncol. 24, 5253-5258.
11. Butts, C.A., Bodkin, D., Middleman, E.L., et al. (2007) Gemcitabine/platinum alone or in combination with cetuximab as first-line treatment for advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. (Meeting Abstracts) 25, 7539.
12. Rosell, R., Daniel, C., Ramlau, R., et al. (2004) Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). J. Clin. Oncol. (Meeting Abstracts) 22, 7012.
13. Saleh, M.N., Socinski, M.A., Trent, D., et al. (2007) Randomized phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small cell lung cancer (NSCLC). J. Clin. Oncol. (Meeting Abstracts) 25, 7586.
14. Pirker, R., Szczesna, A., von Pawel, J., et al. (2008) FLEX: a randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 26, Abstract 3.
15. Lynch, T.J., Patel, T., Dreisbach, L., et al. (2007) A randomized multicenter phase III study of cetuximab (Erbitux) in combiniation with taxane/carboplatin versus taxane/carboplatin alone as first-line treatment for patients with advanced/metastatic non-small lung cancer (NSCLC): B3-03. J. Thorac. Oncol. 2, S340-S341.
16. Brooks, C.S., Tanaka, T., and Munshi, A. (2007) Targeting EGFR Signaling to Enhance Response of Non-Small Cell Lung Cancer Cells to Radiation. Presented at the 2007 American Association for Cancer Research Annual Meeting; April 14-18, Los Angeles, CA. Abstract 3111.
17. Blumenschein, G., Jr., Moughan, J., Curran, W., et al. (2007) A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (pts) with stage III A/B non-small cell lung cancer (NSCLC): an interim report of the RTOG 0324 trial. J Clin Oncol (Meeting Abstracts) 25, 7531.
18. Astsaturov, I., Cohen, R.B., and Harari, P.M. (2006) EGFR-targeting monoclonal antibodies in head and neck cancer. Curr. Cancer Drug Targets 6, 691-710.
19. Bonner, J.A., Harari, P.M., Giralt, J., et al. (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354, 567-578.
20. Curran, D., Giralt, J., Harari, P.M., et al. (2007) Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J. Clin. Oncol. 25, 2191-2197.
21. Vermorken, J.B., Mesia, R., Vega, V., et al. (2007) Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy. Results of a randomized phase III (Extreme) study. J. Clin. Oncol. (Meeting Abstracts) 25, 6091.
22. Pfister, D.G., Su, Y.B., Kraus, D.H., et al. (2006) Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J. Clin. Oncol. 24, 1072-1078.
23. Merlano, M.C., Numico, G., Russi, E.G., et al. (2007) Cetuximab (C-mab) and chemo-radiation (CT-RT) for locoregional advanced squamous cell carcinoma of the head and neck (HNC): a phase II study. J. Clin. Oncol. (Meeting Abstracts) 25, 6043.
24. Vermorken, J.B., Trigo, J., Hitt, R., et al. (2007) Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J. Clin. Oncol. 25, 2171-2177.
25. Sequist, L.V. (2007) Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Oncologist 12, 325-330.
26. Kim, E.S., Kies, M.S., Glisson, B.S., et al. (2007) Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer. J. Clin. Oncol. (Meeting Abstracts) 25, 6013.
27. Soulieres, D., Senzer, N.N., Vokes, E.E., et al. (2004) Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J. Clin. Oncol. 22, 77-85.
28. Bonomi, P. (2003) Clinical studies with non-Iressa EGFR tyrosine kinase inhibitors. Lung Cancer 41(Suppl 1), S43-S48.
29. Vokes, E.E. and Chu, E. (2006) Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers. Oncology (Williston Park) 20, 15-25.
30. Thatcher, N., Chang, A., Parikh, P., et al. (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366, 1527-1537.
31. Kelly, K., Chansky, K., Gaspar, L.E., et al. (2008) Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell-lung cancer: SWOG S0023. J. Clin. Oncol. 26, 2450-2456.
32. Shepherd, F.A., Rodrigues, P.J., Ciuleanu, T., et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353, 123-132.
33. Gridelli, C., Bareschino, M.A., Schettino, C., et al. (2007) Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist 12, 840-849.
34. Hidalgo, M., Siu, L.L., Nemunaitis, J., et al. (2001) Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. 19, 3267-3279.
35. Tsao, M.S., Sakurada, A., Cutz, J.C., et al. (2005) Erlotinib in lung cancer - molecular and clinical predictors of outcome. N. Engl. J. Med. 353, 133-144.
36. Ahmed, S.M. and Salgia, R. (2006) Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. Respirology 11, 687-692.
37. Choong, N.W., Dietrich, S., Seiwert, T.Y., et al. (2006) Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation. Nat. Clin. Pract. Oncol. 3, 50-57.
38. Paz-Ares, L., Sanchez, J.M., Garcia-Velasco, A., et al. (2006) A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). J. Clin. Oncol. (Meeting Abstracts) 24, 7020.
39. Pao, W. and Miller, V.A. (2005) Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J. Clin. Oncol. 23, 2556-2568.
40. Pao, W., Miller, V.A., Politi, K.A., et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, e73. Epub 2005 Feb 22.
41. Rosell, R., Cuello, M., Cecere, F., et al. (2006) Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going. Curr. Opin. Oncol. 18, 135-143.
42. Shimamura, T., Ji, H., Minami, Y., et al. (2006) Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res. 66, 6487-6491.
43. Engelman, J.A., Zejnullahu, K., Mitsudomi, T., et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043.
44. Ma, P.C., Jagadeeswaran, R., Jagadeesh, S., et al. (2005) Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 65, 1479-1488.
45. Sattler, M., Pride, Y.B., Ma, P., et al. (2003) A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res. 63, 5462-5469.
46. Puri, N., Khramtsov, A., Ahmed, S., et al. (2007) A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res. 67, 3529-3534.
47. Sattler, M. and Salgia, R. (2007) c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy. Curr. Oncol. Rep. 9, 102-108.
48. Cappuzzo, F., Hirsch, F.R., Rossi, E., et al. (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl. Cancer Inst. 97, 643-655.
49. Hirsch, F.R., Varella-Garcia, M., McCoy, J., et al. (2005) Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J. Clin. Oncol. 23, 6838-6845.
50. Hirsch, F.R., Varella-Garcia, M., Bunn, P.A., Jr., et al. (2006) Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J. Clin. Oncol. 24, 5034-5042.
51. Italiano, A., Vandenbos, F.B., Otto, J., et al. (2006) Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors. Ann. Oncol. 17, 981-985.
52. Kies, M.S., Ghebremichael, M.S., Katz, T.L., et al. (2007) EGFR expression by immunohistochemistry (IHC) and response to chemotherapy and cetuximab in squamous cell carcinoma of the head and neck (SCCHN). J. Clin. Oncol. (Meeting Abstracts) 25, 6024.
53. Saltz, L.B., Lenz, H., Hochster, H., et al. (2005) Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. J. Clin. Oncol. (Meeting Abstracts) 23, 3508.
54. Vokes, E.E., Cohen, E.E., Mauer, A.M., et al. (2005) A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC). J. Clin. Oncol. (Meeting Abstracts) 23, 5504.
55. Sandler, A. and Herbst, R. (2006) Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways. Clin. Cancer Res. 12, 4421s-4425s.
56. Abidoye, O.O., Cohen, E.E., Wong, S.J., et al. (2006) A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). J. Clin. Oncol. (Meeting Abstracts) 24, 5568.
57. Heymach, J.V., Johnson, B.E., Prager, D., et al. (2006) A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: follow-up results. J. Clin. Oncol. (Meeting Abstracts) 24, 7016.
58. Natale, R.B., Bodkin, D., Govindan, R., et al. (2006) ZD6474 versus gefitinib in patients with advanced NSCLC: final results from a two-part, double-blind, randomized phase II trial. J. Clin. Oncol. (Meeting Abstracts) 24, 7000.